Myriam Arévalo-Herrera1, Kazutoyo Miura2, Eduardo Solano3, Juan Sebastián Ramírez4, Carole A Long2, Giampietro Corradin5, Sócrates Herrera6. 1. Malaria Vaccine and Drug Development Center, Cali, Colombia; Caucaseco Scientific Research Center, Cali, Colombia. Electronic address: marevalo@inmuno.org. 2. Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD 20852, USA. 3. Caucaseco Scientific Research Center, Cali, Colombia. 4. Malaria Vaccine and Drug Development Center, Cali, Colombia. 5. Biochemistry Department, University of Lausanne, Switzerland. 6. Malaria Vaccine and Drug Development Center, Cali, Colombia; Caucaseco Scientific Research Center, Cali, Colombia.
Abstract
BACKGROUND: Pvs48/45 is a Plasmodium vivax gametocyte surface protein involved in the parasite fertilization process. Previous studies showed that Pvs48/45 proteins expressed in Escherichia coli (E. coli) and Chinese hamster ovary (CHO) cells were highly immunoreactive with sera from malaria-endemic areas and highly immunogenic in animal models. Here the immunogenicity in mice of three different vaccine formulations was compared. METHODS: Recombinant (r) Pvs48/45 proteins were expressed in E. coli and CHO, purified, formulated in Alhydrogel, GLA-SE and Montanide ISA-51 adjuvants and used to immunize BALB/c mice. Animals were immunized on days 0, 20 and 40, and serum samples were collected for serological analyses of specific antibody responses using ELISA and immunofluorescence (IFAT). Additionally, ex-vivo transmission-reducing activity (TRA) of sera on P. vivax gametocyte-infected human blood fed to Anopheles albimanus in direct membrane feeding assays (DMFA) was evaluated. RESULTS: Most immunized animals seroconverted after the first immunization, and some developed antibody peaks of 106 with all adjuvants. However, the three adjuvant formulations induced different antibody responses and TRA efficacy. While GLA-SE formulations of both proteins induced similar antibody profiles, Montanide ISA-51 formulations resulted in higher and longer-lasting antibody titers with CHO-rPvs48/45 than with the E. coli formulation. Although the CHO protein formulated in Alhydrogel generated a high initial antibody peak, antibody responses to both proteins rapidly waned. Likewise, anti-Pvs48/45 antibodies displayed differential recognition of the parasite proteins in IFAT and ex vivo blockade of parasite transmission to mosquitoes. The CHO-rPvs48/45 formulated in Montanide ISA-51 induced the most effective ex vivo parasite blockage. CONCLUSIONS: Three out of six vaccine formulations elicited antibodies with ex vivo TRA. The CHO-rPvs48/45 Montanide ISA-51 formulation induced the most stable antibody response, recognizing the native protein and the most robust ex vivo TRA. These results encourage further testing of the vaccine potential of this protein.
BACKGROUND: Pvs48/45 is a Plasmodium vivax gametocyte surface protein involved in the parasite fertilization process. Previous studies showed that Pvs48/45 proteins expressed in Escherichia coli (E. coli) and Chinese hamster ovary (CHO) cells were highly immunoreactive with sera from malaria-endemic areas and highly immunogenic in animal models. Here the immunogenicity in mice of three different vaccine formulations was compared. METHODS: Recombinant (r) Pvs48/45 proteins were expressed in E. coli and CHO, purified, formulated in Alhydrogel, GLA-SE and Montanide ISA-51 adjuvants and used to immunize BALB/c mice. Animals were immunized on days 0, 20 and 40, and serum samples were collected for serological analyses of specific antibody responses using ELISA and immunofluorescence (IFAT). Additionally, ex-vivo transmission-reducing activity (TRA) of sera on P. vivax gametocyte-infected human blood fed to Anopheles albimanus in direct membrane feeding assays (DMFA) was evaluated. RESULTS: Most immunized animals seroconverted after the first immunization, and some developed antibody peaks of 106 with all adjuvants. However, the three adjuvant formulations induced different antibody responses and TRA efficacy. While GLA-SE formulations of both proteins induced similar antibody profiles, Montanide ISA-51 formulations resulted in higher and longer-lasting antibody titers with CHO-rPvs48/45 than with the E. coli formulation. Although the CHO protein formulated in Alhydrogel generated a high initial antibody peak, antibody responses to both proteins rapidly waned. Likewise, anti-Pvs48/45 antibodies displayed differential recognition of the parasite proteins in IFAT and ex vivo blockade of parasite transmission to mosquitoes. The CHO-rPvs48/45 formulated in Montanide ISA-51 induced the most effective ex vivo parasite blockage. CONCLUSIONS: Three out of six vaccine formulations elicited antibodies with ex vivo TRA. The CHO-rPvs48/45 Montanide ISA-51 formulation induced the most stable antibody response, recognizing the native protein and the most robust ex vivo TRA. These results encourage further testing of the vaccine potential of this protein.
Authors: Kazutoyo Miura; Andrew C Orcutt; Olga V Muratova; Louis H Miller; Allan Saul; Carole A Long Journal: Vaccine Date: 2007-11-20 Impact factor: 3.641
Authors: Richard G A Feachem; Ingrid Chen; Omar Akbari; Amelia Bertozzi-Villa; Samir Bhatt; Fred Binka; Maciej F Boni; Caroline Buckee; Joseph Dieleman; Arjen Dondorp; Alex Eapen; Neelam Sekhri Feachem; Scott Filler; Peter Gething; Roly Gosling; Annie Haakenstad; Kelly Harvard; Arian Hatefi; Dean Jamison; Kate E Jones; Corine Karema; Richard Nchabi Kamwi; Altaf Lal; Erika Larson; Margaret Lees; Neil F Lobo; Angela E Micah; Bruno Moonen; Gretchen Newby; Xiao Ning; Muhammad Pate; Martha Quiñones; Michelle Roh; Ben Rolfe; Dennis Shanks; Balbir Singh; Kenneth Staley; James Tulloch; Jennifer Wegbreit; Hyun Ju Woo; Winnie Mpanju-Shumbusho Journal: Lancet Date: 2019-09-08 Impact factor: 79.321
Authors: William E Collins; John W Barnwell; Joann S Sullivan; Douglas Nace; Tyrone Williams; Amy Bounngaseng; Jacquelin Roberts; Elizabeth Strobert; Harold McClure; Allan Saul; Carole A Long Journal: Am J Trop Med Hyg Date: 2006-02 Impact factor: 2.345
Authors: Yimin Wu; Ruth D Ellis; Donna Shaffer; Erica Fontes; Elissa M Malkin; Siddhartha Mahanty; Michael P Fay; David Narum; Kelly Rausch; Aaron P Miles; Joan Aebig; Andrew Orcutt; Olga Muratova; Guanhong Song; Lynn Lambert; Daming Zhu; Kazutoyo Miura; Carole Long; Allan Saul; Louis H Miller; Anna P Durbin Journal: PLoS One Date: 2008-07-09 Impact factor: 3.240
Authors: Andres F Vallejo; Nora L Martinez; Alejandra Tobon; Jackeline Alger; Marcus V Lacerda; Andrey V Kajava; Myriam Arévalo-Herrera; Sócrates Herrera Journal: Malar J Date: 2016-04-12 Impact factor: 2.979
Authors: Frankie M T Lyons; Mikha Gabriela; Wai-Hong Tham; Melanie H Dietrich Journal: Front Cell Infect Microbiol Date: 2022-07-08 Impact factor: 6.073